All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-11-16T08:58:08.000Z

R-HDS followed by ASCT is as effective as R-CHOP14

Nov 16, 2016
Share:

Bookmark this article

S. Cortelazzo presented with his Italian colleagues the results of a randomized open-label, multicenter phase III trial performed in 246 high-risk DLBCL with high-intermediate (56%) or high IPI score who received either R-CHOP14 during 8 cycles or R-HDS (high-sequential chemotherapy) with autologous stem cell transplantation. They published their results in J Clin Oncol in October 2016.

Their key findings are:

  • No significant difference in CR or CRu rates between the 2 arms (78% R-CHOP, 76% R-HDS, p=0.74)
  • No significant difference in ORR: 83% vs 85% (p=0.65)
  • 3-year EFS: no difference between R-CHOP (62%) and R-HDS (65%), p=0.83
  • 3-year DFS: R-CHOP, 79% vs 91% (R-HDS), p =0.033, but late relapses in the R-HDS group leading to a non-significant difference in DFS between the 2 regimens at 7 years.
  • No difference in OS (74% vs 77%, p=0.64)
  • Significantly lower hematological toxicity (neutropenia, anemia, thrombocytopenia), lower frequency of severe infections, lower number of AEs including the serious AEs, fewer episodes of GI toxicity in the R-CHOP arm

In conclusion, in high-risk DLBCL, R-HDS followed by ASCT and R-CHOP14 were equally effective.

Abstract

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-cell lymphomas is still a matter of debate. To address this point, we designed a randomized phase III trial to compare rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) with rituximab plus high-dose sequential chemotherapy (R-HDS) with ASCT.

Patients and Methods From June 2005 to June 2011, 246 high-risk patients with a high-intermediate (56%) or high (44%) International Prognostic Index score were randomly assigned to the R-CHOP or R-HDS arm, and 235 were analyzed by intent to treat. The primary efficacy end point of the study was 3-year event-free survival, and results were analyzed on an intent-to-treat basis.

Results Clinical response (complete response, 78% v 76%; partial response, 5% v9%) and failures (no response, 15% v 11%; and early treatment-related mortality, 2%v 3%) were similar after R-CHOP versus R-HDS, respectively. After a median follow-up of 5 years, the 3-year event-free survival was 62% versus 65% (P = .83). At 3 years, compared with the R-CHOP arm, the R-HDS arm had better disease-free survival (79% v 91%, respectively; P = .034), but this subsequently vanished because of late-occurring treatment-related deaths. No difference was detected in terms of progression-free survival (65% v 75%, respectively; P = .12), or overall survival (74%v 77%, respectively; P = .64). Significantly higher hematologic toxicity (P < .001) and more infectious complications (P < .001) were observed in the R-HDS arm.

Conclusion In this study, front-line intensive R-HDS chemotherapy with ASCT did not improve the outcome of high-risk patients with diffuse large B-cell lymphomas.

  1. S. Cortelazzo et al. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas J Clin Oncol  Published online ahead of print October 2016. doi: 10.1200/JCO.2016.67.2980

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox